Pacira Biosciences Inc
NASDAQ:PCRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pacira Biosciences Inc
Revenue
Pacira Biosciences Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Pacira Biosciences Inc
NASDAQ:PCRX
|
Revenue
$726.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$96.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$48.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$62.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$65B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$65.2B
|
CAGR 3-Years
32%
|
CAGR 5-Years
22%
|
CAGR 10-Years
13%
|
|
Pacira Biosciences Inc
Glance View
Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
See Also
What is Pacira Biosciences Inc's Revenue?
Revenue
726.4m
USD
Based on the financial report for Dec 31, 2025, Pacira Biosciences Inc's Revenue amounts to 726.4m USD.
What is Pacira Biosciences Inc's Revenue growth rate?
Revenue CAGR 10Y
11%
Over the last year, the Revenue growth was 4%. The average annual Revenue growth rates for Pacira Biosciences Inc have been 3% over the past three years , 11% over the past five years , and 11% over the past ten years .